TMCnet News
Personalis Introduces New Services for Cancer Research and Clinical TrialsMENLO PARK, Calif. & SAN DIEGO --(Business Wire)-- Personalis, Inc., a leading genomics-based service provider, today announced it is launching an expanded portfolio of cancer research solutions based on its ACE (Accuracy and Content Enhanced) sequencing, informatics and content technology platform. Scientists from Personalis presented the new portfolio of cancer research solutions this weekend to attendees at the 2014 American Society of Human Genetics Annual Meeting taking place through Wednesday in San Diego. At the center of Personalis' cancer research products is a core set of more than 1,300 protein-coding genes and more than 200 miRNA genes related to cancer. This gene set provides more coverage of gene pathways and functions known to be involved in cancer biology than any other commercially available panel. Personalis supports this common gene set in both panel and exome configurations. Both combine DNA and RNA assays, which can be performed from a single common sample, and use Personalis ACE technology to improve coverage uniformity and complete the sequencing of difficult genes. Both configurations also include key content outside the coding regions. The ACE Exome for Cancer prvides data from the common gene set in the broader context of more than 8,000 medically related genes with augmented coverage, and 20,000 genes overall. The ACE Extended Cancer Panel targets the same broad cancer gene set, but achieves over 500x average sequencing coverage, for optimum sensitivity to alleles from rare cell subpopulations. Personalis offers this end-to-end service starting with a broad range of sample types, including FFPE blocks, Fine Needle Aspirates, core biopsies and fresh frozen tissue. By combining DNA and RNA analysis, Personalis provides a comprehensive tumor genomic profile. DNA and RNA assays are matched to cover the same gene sets, either at the exome level or the panel level. Personalis' cancer data analysis pipeline integrates the DNA and RNA results, providing a more comprehensive understanding than would be possible from either independently. This includes detection of fusion transcripts and allelic expression, as well as gene expression. None of these would be well reported with DNA analysis alone. More information, including a comprehensive brochure detailing these new offerings is available for download at: www.personalis.com/cancer. Research Use Only Personalis' genetic testing services for cancer applications are being initially offered for research use only. They have not yet been CLIA validated, and they have not been submitted for review by the US FDA or any other regulatory agency. About Personalis, Inc. Personalis, Inc. provides researchers advanced genome-scale sequencing and interpretation services for inherited genetic disease and cancer. For more information please visit www.personalis.com.
|
